1. Introduction {#sec0005}
===============

With an incidence of 0.29/100.000 the malignant forms of neuroendocrine neoplasms of the small intestine are a rather rare entity.[@bib0005; @bib0010; @bib0015; @bib0020] Though they represent about 30-50% of all small intestine neoplasms and hence are of high clinical importance.[@bib0005] Current literature does not present precise data on recurrence rate in low grade neuroendocrine tumors (NET).[@bib0015; @bib0020; @bib0025; @bib0030; @bib0035] The tumor proliferation rate, measured with help of Ki-67 has not only been established for grading neuroendocrine tumors, but it is also of prognostic value for possible tumor recurrence. Following the ENETS guidelines close follow-up is necessary even after complete tumor resection and even in slow proliferating tumors. In this case report we present a 64 year old female with recurrence of a slow proliferating neuroendocrine tumor (Ki-67 \< 1%) in two locations of the small intestine at the same time.

2. Presentation of case {#sec0010}
=======================

A 64 year old female with several carcinomas in her family history (among others colorectal and gastric) underwent annually screening tests including measurement of CA-19.9. In January 2009 an asymptomatic elevation of CA-19.9 (80.3 ku/l) lead to an abdominal CT scan revealing a lesion with hypertrophic and hypervascular wall of the small intestinal. Reanalysis with CT scan after 3 months verified a hypodense, intraluminal lesion, 14 mm in diameter. Diagnostic laparoscopy with segmental gut resection was performed and an intraoperative pathologic examination requested. Histological findings classified the resected tumor as a high differentiated neuroendocrine carcinoma with local lymph node involvement (pT4, N1 (4/9), L1, V0, G1, R0). In consequence Chromogranin A levels have been measured postoperatively, not showing pathologic values (43 μg/l). Further staging analysis using somatostatin receptor scintigraphy (SRS) did not indicate any metastasis.

Due to the slow proliferation rate (Ki-67 \< 1%) semiannual follow-up examinations including CT scan and measurements of Chromogranin A levels were carried out like proposed in the current ENETS guidelines.[@bib0015; @bib0020] CT scan in December 2012 revealed hypertrophy of the intestinal wall again, this time in two locations simultaneously. With the patient asymptomatic and tumor markers at normal levels, active surveillance was performed for further 6 months and finally Ga-DOTATOC-PET/CT was done, verifying two intraluminal lesions of the small intestine measuring 15 mm in diameter ([Figs. 1 and 2](#fig0005 fig0010){ref-type="fig"}). Therefore diagnostic laparoscopy with resection of the two affected gut segments via mini-laparotomy was performed. The tumors were localized in the proximal ileum, about 100 cm oral from the ileocecal region, with a distance of 25 cm between each other. This time histological exams classified the tumors as high differentiated neuroendocrine carcinomas, the proximal one even with regional lymph node involvement (pT2, pN1 (1/1), G1 and pT1, pN0, G1) ([Fig. 3](#fig0015){ref-type="fig"}). Proliferation rate was slow again with Ki-67 less than 1%.

3. Discussion {#sec0015}
=============

Tumor grading in this case described a high differentiated and slow proliferating NET with Ki-67 \< 1%. Despite low proliferation and high differentiation we found a bilocal tumor recurrence. With a distance of 25 cm between the two lesions we can assume an independent process of growth. A case of bilocal recurrence has not yet been described explicitly and is rather uncommon. Regarding recurrence of NET after surgical R0 resection only two publications are considered in current guidelines. Moertel described that only 23% of the patients that underwent curative surgery were free of disease after 25 years.[@bib0025] Second one is Pape et al. who present 52 cases of tumor recurrence after surgical R0 resection in 139 patients (37.4%).[@bib0030] Due to such a lack of long-term results further studies on recurrence rate and typical localization should be made ([Fig. 4](#fig0020){ref-type="fig"}).

Diagnostic procedures and operative treatment in this case were performed according to ENET guidelines with follow-up imaging every 6--12 months. Between the two tumor manifestations in 2009 and 2013 technical development led to a change in diagnostic procedures. Following ENETS guidelines in 2007 SRS has been proposed for imaging of neuroendocrine tumors. Latest guidelines from 2012 prefer Ga-DOTATOC-PET/CT, if available, because of its higher sensitivity.[@bib0015; @bib0020; @bib0040; @bib0045; @bib0050; @bib0055] Therefore SRS has been used in 2009 whereas PET-CT revealed tumor recurrence in 2013. Both times tumor manifestation has been recognized in early state. As PET-CT provides higher sensitivity, detection of two additional but preexisting lesions which had been missed by SRS in 2009 is theoretically possible but rather unlikely. For instance assume a bilocal recurrence after curative surgical treatment.

4. Conclusion {#sec0020}
=============

According recurrence rate of neuroendocrine tumors only few data is presented in current literature and hence considered in common guidelines. Coming research should focus on recurrence rate and long-time outcomes, especially after R0 resection, of neuroendocrine tumors so that follow-up procedures could be adapted. Following the ENETS guidelines livelong follow-up is essential and Ga-DOTATOC-PET/CT should nowadays be the diagnostic item of choice, if available. Even in this case of bilocal tumor recurrence early tumor detection was possible.
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